New campaign aims to inform and educate the public about the ongoing risks of COVID-19 and the impact the virus continues to have on day-to-day life
Updated vaccines targeting KP.2 variant have been approved by the U.S. FDA and are now available across the country
Read MoreMMJ International Holdings has submitted to the FDA for approval of its soft gelatin capsule to be used in clinical trails for its Huntington Disease Study. MMJ has received an Orphan designation from the FDA. Once FDA approved the company will be one of a very few with federal authorization to sell its medication.
Read More
New patent issued for core rare disease target indication for crofelemer
Napo has approximately 230 patents issued and pending
Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025
Read More
Milgram's public statements, juxtaposed with the DEA's restrictive actions, paint a picture of an agency at odds with itself-one that claims to prioritize public health while simultaneously obstructing access to innovative treatments that could save lives. As the legal and public pressure mounts, the DEA may be forced to reconsider its approach, leading to a new era of drug policy in America
Read MoreMagdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications
Read MoreNew patent issued for core rare disease target indication for crofelemer
Napo has approximately 230 patents issued and pending
Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025
Read More
